Modified iRNA agents
US9394540B2 · kind B2 · utility
1Cited by
8References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 19, 2014 |
| Grant date | Jul 19, 2016 |
| Priority date | — |
| Expiry date | May 19, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2330/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to iRNA agents, which preferably include a monomer in which the ribose moiety has been replaced by a moiety other than ribose. The inclusion of such a monomer can allow for modulation of a property of the iRNA agent into which it is incorporated, e.g., by using the non-ribose moiety as a point to which a ligand or other entity, e.g., a lipophilic moiety. e.g., cholesterol, is directly, or indirectly, tethered. The invention also relates to methods of making and using such modified iRNA agents.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.